4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States
240 497 9024
https://www.nwbio.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 25
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Ms. Linda F. Powers J.D. | Chairperson, CEO, President, CFO & Chief Accounting Officer | 925k | S.O. | 1956 |
Dr. Alton L. Boynton Ph.D. | Founder, Chief Scientific Officer, Secretary & Director | 375k | S.O. | 1945 |
Dr. Marnix L. Bosch M.B.A., Ph.D. | Chief Technical Officer | 453,6k | 74k | 1959 |
Mr. Leslie J. Goldman | Senior VP & General Counsel | 725k | S.O. | 1945 |
Mr. David Innes | Vice President of Investor Relations | S.O. | S.O. | S.O. |
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
L’ISS Governance QualityScore de Northwest Biotherapeutics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..